本网站使用浏览器纪录(Cookies)来提供您最好的使用体验,相关资讯请访问我们的隐私政策。如果您选择继续浏览或关闭这个提示,便表示您已接受我们的网站使用条款。 关闭

Sildenafil, cas139755-83-2, 99%, for bodybuilding

2022/06/29
  • LINE
  • Twitter
  • LinkedIn
Sildenafil,  cas139755-83-2, 99%, for bodybuilding

Sildenafil was the world's first oral PDE5 inhibitor (phosphodiesterase type 5 inhibitor) for the treatment of erectile dysfunction (also known as impotence or ED), revolutionizing the treatment of ED and effectively improving penile erection hardness.

Sildenafil has been on the market for more than 10 years. Oral drugs represented by sildenafil have been recommended as first-line treatment for ED by medical guidelines in many countries and regions (such as the United States, Europe, China, Japan, etc.).

Pharmacological effects of sildenafil:

(1) Effect of sildenafil on penile erectile response. Sildenafil is a highly selective phosphodiesterase 5(PDE5) inhibitor, which is highly expressed in the cavernous body of the p and is low expressed in other tissues, including platelets, blood vessels and visceral smooth muscle, and skeletal muscle. Sildenafil can selectively inhibit PDE5, enhance the nitric oxide (NO)-cGMP pathway, and increase the level of cGMP, resulting in the relaxation of the cavernosial smooth muscle of the p, so that patients with erectile dysfunction can produce a natural erectile response to sexual stimulation. Erectile response is generally enhanced with increasing sildenafil dose and plasma concentration. Experiments showed that the effect lasted up to 4 hours, but the response was weaker than that at 2 hours.


(2) Response of sildenafil to myocardium. PDE5 does not exist in normal or pathological cardiac conduction tissues, cardiomyocytes, endothelial cells, and lymphoid tissues. Therefore, sildenafil (PDE5 inhibitor) has no positive inotropic effect and cannot directly affect myocardial systolic function.


(3) The effect of sildenafil on cardiac parameters. No clinically significant ECG changes were observed in normal male volunteers with a single dose of sildenafil 100mg. Eight patients with stable ischemic heart disease received a total of 40mg of sildenafil in four intravenous doses monitored by a Swan-Ganz catheter. Systolic and diastolic blood pressure at rest decreased by 7% and 10%, respectively, from baseline. Rest right atrium, pulmonary artery pressure, pulmonary wedge pressure, and cardiac output decreased by an average of 28%, 28%, 20%, and 7%, respectively. Although this intravenous dose was 2 to 5 times higher than the average peak plasma concentration of 100mg of sildenafil in a single dose of oral sildenafil in healthy male volunteers, these hemodynamic responses remained during exercise.

为您推荐

浏览记录
    询价清单